A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.


Updates from The Motley Fool

Latest updates on Amicus Therapeutics from Fool.com.


Stock Performance

FOLD vs. S&P 500 | 2 Year Performance
View Interactive FOLD Charts
Sponsored by

Key Data Points

Primary metrics and data points about Amicus Therapeutics.
Current Price: $7.01
Prev Close: $6.98
Open: $7.01
Bid: $6.65
Ask: $7.09
Day's Range: $6.65 - $7.10
52wk Range: $4.98 - $18.40
Volume: 1,781,029
Avg Vol 2,279,507
Market Cap: $875.55M
P/E (ttm): -4.92
EPS (ttm): -$1.42
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Amicus Therapeutics.
CAPS Rating 3 out of 5
 
105 Outperform
25 Underperform
CAPS All Stars
 
22 Outperform
8 Underperform

How do you think Amicus Therapeutics will perform against the market?



You pick for Amicus Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John F. Crowley, CEO

100% Approve

Based on 9 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Amicus Therapeutics.

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers